APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dipeptide Peptidase 4 (DPP-4) Inhibitors

Compare research editions
View pricing & licenses

Selected research

Industry Research

Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Research Report 2026

20 December 2025119 pages

Choose your research edition.

Industry ResearchDipeptide Peptidase 4 (DPP-4) Inhibitors Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Dipeptide Peptidase 4 (DPP-4) Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Dipeptide Peptidase 4 (DPP-4) Inhibitors market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Dipeptide Peptidase 4 (DPP-4) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Dipeptide Peptidase 4 (DPP-4) Inhibitors is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Dipeptide Peptidase 4 (DPP-4) Inhibitors is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Dipeptide Peptidase 4 (DPP-4) Inhibitors include Takeda Pharmaceutical Company, Merck, Eli Lilly, Boehringer Ingelheim, BMS and AstraZenica, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Dipeptide Peptidase 4 (DPP-4) Inhibitors market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Dipeptide Peptidase 4 (DPP-4) Inhibitors Market by Company

Takeda Pharmaceutical Company

Merck

Eli Lilly

Boehringer Ingelheim

BMS

AstraZenica

Dipeptide Peptidase 4 (DPP-4) Inhibitors Segment by Type

Alogliptin

Linagliptin

Sitagliptin

Saxagliptin

Vildagliptin

Dipeptide Peptidase 4 (DPP-4) Inhibitors Segment by Application

Hospitals

Clinics

Dipeptide Peptidase 4 (DPP-4) Inhibitors Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dipeptide Peptidase 4 (DPP-4) Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dipeptide Peptidase 4 (DPP-4) Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dipeptide Peptidase 4 (DPP-4) Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Dipeptide Peptidase 4 (DPP-4) Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Dipeptide Peptidase 4 (DPP-4) Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Dipeptide Peptidase 4 (DPP-4) Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 8. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue of Manufacturers (2021-2026) Table 9. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Dipeptide Peptidase 4 (DPP-4) Inhibitors Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Dipeptide Peptidase 4 (DPP-4) Inhibitors, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Dipeptide Peptidase 4 (DPP-4) Inhibitors, Product Type & Application Table 14. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Takeda Pharmaceutical Company Company Information Table 19. Takeda Pharmaceutical Company Business Overview Table 20. Takeda Pharmaceutical Company Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Takeda Pharmaceutical Company Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio Table 22. Takeda Pharmaceutical Company Recent Developments Table 23. Merck Company Information Table 24. Merck Business Overview Table 25. Merck Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Merck Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio Table 27. Merck Recent Developments Table 28. Eli Lilly Company Information Table 29. Eli Lilly Business Overview Table 30. Eli Lilly Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Eli Lilly Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio Table 32. Eli Lilly Recent Developments Table 33. Boehringer Ingelheim Company Information Table 34. Boehringer Ingelheim Business Overview Table 35. Boehringer Ingelheim Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Boehringer Ingelheim Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio Table 37. Boehringer Ingelheim Recent Developments Table 38. BMS Company Information Table 39. BMS Business Overview Table 40. BMS Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. BMS Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio Table 42. BMS Recent Developments Table 43. AstraZenica Company Information Table 44. AstraZenica Business Overview Table 45. AstraZenica Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. AstraZenica Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio Table 47. AstraZenica Recent Developments Table 48. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 49. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region (2021-2026) & (K Units) Table 50. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Region (2021-2026) Table 51. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region (2027-2032) & (K Units) Table 52. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Region (2027-2032) Table 53. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 54. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Region (2021-2026) Table 55. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 56. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Region (2027-2032) Table 57. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2021-2026) & (K Units) Table 59. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2027-2032) & (K Units) Table 60. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 61. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 62. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2021-2026) & (K Units) Table 64. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2027-2032) & (K Units) Table 65. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 66. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 67. Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 68. Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2021-2026) & (K Units) Table 69. Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2027-2032) & (K Units) Table 70. Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 71. Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 72. South America Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. South America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2021-2026) & (K Units) Table 74. South America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2027-2032) & (K Units) Table 75. South America Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 76. South America Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 77. Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2021-2026) & (K Units) Table 79. Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2027-2032) & (K Units) Table 80. Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 81. Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 82. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Type (2021-2026) & (K Units) Table 83. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Type (2027-2032) & (K Units) Table 84. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Type (2021-2026) Table 85. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Type (2027-2032) Table 86. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 87. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 88. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Type (2021-2026) Table 89. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Type (2027-2032) Table 90. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Price by Type (2021-2026) & (US$/Unit) Table 91. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Price by Type (2027-2032) & (US$/Unit) Table 92. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Application (2021-2026) & (K Units) Table 93. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Application (2027-2032) & (K Units) Table 94. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Application (2021-2026) Table 95. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Application (2027-2032) Table 96. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 97. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 98. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Application (2021-2026) Table 99. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Application (2027-2032) Table 100. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Price by Application (2021-2026) & (US$/Unit) Table 101. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Price by Application (2027-2032) & (US$/Unit) Table 102. Key Raw Materials Table 103. Raw Materials Key Suppliers Table 104. Dipeptide Peptidase 4 (DPP-4) Inhibitors Distributors List Table 105. Dipeptide Peptidase 4 (DPP-4) Inhibitors Customers List Table 106. Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Trends Table 107. Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Drivers Table 108. Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Restraints Table 109. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Image Figure 5. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size (2021-2032) & (US$ Million) Figure 7. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (2021-2032) & (K Units) Figure 8. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Average Price (US$/Unit) & (2021-2032) Figure 9. Alogliptin Product Image Figure 10. Linagliptin Product Image Figure 11. Sitagliptin Product Image Figure 12. Saxagliptin Product Image Figure 13. Vildagliptin Product Image Figure 14. Hospitals Product Image Figure 15. Clinics Product Image Figure 16. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Dipeptide Peptidase 4 (DPP-4) Inhibitors, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Dipeptide Peptidase 4 (DPP-4) Inhibitors Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region in 2025 Figure 22. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Region in 2025 Figure 23. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size by Country in 2025 Figure 24. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Country (2021-2032) Figure 25. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Country (2021-2032) Figure 26. United States Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size by Country in 2025 Figure 29. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Country (2021-2032) Figure 30. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Country (2021-2032) Figure 31. Germany Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Netherlands Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Nordic Countries Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size by Country in 2025 Figure 38. Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Country (2021-2032) Figure 39. Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Country (2021-2032) Figure 40. China Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Japan Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. South Korea Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. India Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Australia Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. China Taiwan Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Southeast Asia Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Southeast Asia Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size by Country in 2025 Figure 49. South America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Country (2021-2032) Figure 50. South America Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Country (2021-2032) Figure 51. Mexico Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Brazil Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Argentina Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size by Country in 2025 Figure 55. Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Country (2021-2032) Figure 56. Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Country (2021-2032) Figure 57. Turkey Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Saudi Arabia Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. UAE Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Type (2021-2032) Figure 61. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Type (2021-2032) Figure 62. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Price (US$/Unit) by Type (2021-2032) Figure 63. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Application (2021-2032) Figure 64. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Application (2021-2032) Figure 65. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Price (US$/Unit) by Application (2021-2032) Figure 66. Dipeptide Peptidase 4 (DPP-4) Inhibitors Value Chain Figure 67. Dipeptide Peptidase 4 (DPP-4) Inhibitors Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Opportunities and Challenges

Scope & coverage.

Types
  • Alogliptin
  • Linagliptin
  • Sitagliptin
  • Saxagliptin
  • Vildagliptin
Applications
  • Hospitals
  • Clinics
Companies covered
  • Takeda Pharmaceutical Company
  • Merck
  • Eli Lilly
  • Boehringer Ingelheim
  • BMS
  • AstraZenica

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size (2021-2032)
  4. 2.2.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (2021-2032)
  5. 2.2.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Average Price (2021-2032)
  6. 2.3 Dipeptide Peptidase 4 (DPP-4) Inhibitors by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Alogliptin
  9. 2.3.3 Linagliptin
  10. 2.3.4 Sitagliptin
  11. 2.3.5 Saxagliptin
  12. 2.3.6 Vildagliptin
  13. 2.4 Dipeptide Peptidase 4 (DPP-4) Inhibitors by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Hospitals
  16. 2.4.3 Clinics
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Dipeptide Peptidase 4 (DPP-4) Inhibitors, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Dipeptide Peptidase 4 (DPP-4) Inhibitors, Product Type & Application
  8. 3.8 Global Manufacturers of Dipeptide Peptidase 4 (DPP-4) Inhibitors, Established Date
  9. 3.9 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Takeda Pharmaceutical Company
  2. 4.1.1 Takeda Pharmaceutical Company Company Information
  3. 4.1.2 Takeda Pharmaceutical Company Business Overview
  4. 4.1.3 Takeda Pharmaceutical Company Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Takeda Pharmaceutical Company Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio
  6. 4.1.5 Takeda Pharmaceutical Company Recent Developments
  7. 4.2 Merck
  8. 4.2.1 Merck Company Information
  9. 4.2.2 Merck Business Overview
  10. 4.2.3 Merck Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Merck Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio
  12. 4.2.5 Merck Recent Developments
  13. 4.3 Eli Lilly
  14. 4.3.1 Eli Lilly Company Information
  15. 4.3.2 Eli Lilly Business Overview
  16. 4.3.3 Eli Lilly Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Eli Lilly Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio
  18. 4.3.5 Eli Lilly Recent Developments
  19. 4.4 Boehringer Ingelheim
  20. 4.4.1 Boehringer Ingelheim Company Information
  21. 4.4.2 Boehringer Ingelheim Business Overview
  22. 4.4.3 Boehringer Ingelheim Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Boehringer Ingelheim Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio
  24. 4.4.5 Boehringer Ingelheim Recent Developments
  25. 4.5 BMS
  26. 4.5.1 BMS Company Information
  27. 4.5.2 BMS Business Overview
  28. 4.5.3 BMS Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 BMS Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio
  30. 4.5.5 BMS Recent Developments
  31. 4.6 AstraZenica
  32. 4.6.1 AstraZenica Company Information
  33. 4.6.2 AstraZenica Business Overview
  34. 4.6.3 AstraZenica Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 AstraZenica Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio
  36. 4.6.5 AstraZenica Recent Developments
5 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Scenario by Region
  1. 5.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region: 2021-2032
  3. 5.2.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region: 2021-2026
  4. 5.2.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region: 2027-2032
  5. 5.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Region: 2021-2032
  6. 5.3.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Region: 2021-2026
  7. 5.3.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Region: 2027-2032
  8. 5.4 North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Facts & Figures by Country
  9. 5.4.1 North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2021-2032)
  11. 5.4.3 North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Facts & Figures by Country
  15. 5.5.1 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2021-2032)
  17. 5.5.3 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.5.9 Nordic Countries
  24. 5.6 Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Facts & Figures by Country
  25. 5.6.1 Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  26. 5.6.2 Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2021-2032)
  27. 5.6.3 Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country (2021-2032)
  28. 5.6.4 China
  29. 5.6.5 Japan
  30. 5.6.6 South Korea
  31. 5.6.7 India
  32. 5.6.8 Australia
  33. 5.6.9 China Taiwan
  34. 5.6.10 Southeast Asia
  35. 5.7 South America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Facts & Figures by Country
  36. 5.7.1 South America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  37. 5.7.2 South America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2021-2032)
  38. 5.7.3 South America Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country (2021-2032)
  39. 5.7.4 Mexico
  40. 5.7.5 Brazil
  41. 5.7.6 Argentina
  42. 5.8 Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Facts & Figures by Country
  43. 5.8.1 Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  44. 5.8.2 Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2021-2032)
  45. 5.8.3 Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country (2021-2032)
  46. 5.8.4 Turkey
  47. 5.8.5 Saudi Arabia
  48. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Type (2021-2032)
  2. 6.1.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Type (2021-2032)
  4. 6.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Type (2021-2032)
  5. 6.2.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Application (2021-2032)
  2. 7.1.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Application (2021-2032)
  4. 7.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Application (2021-2032)
  5. 7.2.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Dipeptide Peptidase 4 (DPP-4) Inhibitors Value Chain Analysis
  2. 8.1.1 Dipeptide Peptidase 4 (DPP-4) Inhibitors Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Dipeptide Peptidase 4 (DPP-4) Inhibitors Production Mode & Process
  5. 8.2 Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Dipeptide Peptidase 4 (DPP-4) Inhibitors Distributors
  8. 8.2.3 Dipeptide Peptidase 4 (DPP-4) Inhibitors Customers
9 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Analyzing Market Dynamics
  1. 9.1 Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Trends
  2. 9.2 Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Drivers
  3. 9.3 Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Opportunities and Challenges
  4. 9.4 Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst